87-12-7

Basic information

• Product Name: dibromsalan
• Synonyms: dibromsalan;5-Bromo-N-(4-bromophenyl)-2-hydroxybenzamide;5-Bromo-N-(4-bromophenyl)salicylamide;NSC-20527
• CAS NO: 87-12-7
• Molecular Formula: C₁₃H₉Br₂NO₂
• Molecular Weight: 371.05
• EINECS: 201-724-1
• Mol File: 87-12-7.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 387.8°C at 760 mmHg
• Flash Point: 188.4°C
• Appearance: /
• Density: 1.7990 (rough estimate)
• Vapor Pressure: 1.43E-06mmHg at 25°C
• Refractive Index: 1.6220 (estimate)
• CAS DataBase Reference: dibromsalan(CAS DataBase Reference)
• NIST Chemistry Reference: dibromsalan(87-12-7)
• EPA Substance Registry System: dibromsalan(87-12-7)

Safety Data

• Hazardous Substances Data: 87-12-7(Hazardous Substances Data)

Usage

Uses

Disinfectant.

InChI:InChI=1/C13H9Br2NO2/c14-8-1-4-10(5-2-8)16-13(18)11-7-9(15)3-6-12(11)17/h1-7,17H,(H,16,18)

Upstream product

• 87-17-2 salicylanilide 
• 89-55-4 5-bromosalicyclic acid 
• 106-40-1 4-bromo-aniline 
• 17464-66-3 5-Bromosalicyloyl chloride 

Downstream Products

• 50736-83-9 6-bromo-3-(4-bromo-phenyl)-2-trifluoromethylimino-2,3-dihydro-benzo[e][1,3]oxazin-4-one 
• 1552270-24-2 4-bromo-2-[(4-bromophenyl)carbamoyl]phenyl diethyl phosphate 
• 5596-25-8 6-bromo-3-(4-bromo-phenyl)-benzo[e][1,3]oxazine-2,4-dione 

Relevant articles and documents

2-Hydroxy-N-Phenylbenzamides and their esters inhibit acetylcholinesterase and Butyrylcholinesterase

The development of novel inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) represents a viable approach to alleviate Alzheimer’s disease. Thirty-six halogenated 2-hydroxy-N-phenylbenzamides (salicylanilides) with various substitution patterns and their esters with phosphorus-based acids were synthesized in yields of 72% to 92% and characterized. They were evaluated for in vitro inhibition of AChE from electric eel and BuChE from equine serum using modified Ellman’s spectrophotometric method. The benzamides exhibited a moderate inhibition of AChE with IC50 values in a narrow concentration range from 33.1 to 85.8 μM. IC50 values for BuChE were higher (53.5–228.4 μM). The majority of derivatives inhibit AChE more efficiently than BuChE and are comparable or superior to rivastigmine—an established cholinesterases inhibitor used in the treatment of Alzheimer’s disease. Phosphorus-based esters especially improved the activity against BuChE with 5-chloro-2-{[4-(trifluoromethyl)phenyl]carbamoyl}phenyl diethyl phosphite 5c superiority (IC50 = 2.4 μM). This derivative was also the most selective inhibitor of BuChE. It caused a mixed inhibition of both cholinesterases and acted as a pseudo-irreversible inhibitor. Several structure-activity relationships were identified, e.g., favouring esters and benzamides obtained from 5-halogenosalicylic acids and polyhalogenated anilines. Both 2-hydroxy-N-phenylbenzamides and esters share convenient physicochemical properties for blood-brain-barrier penetration and thus central nervous system delivery.

Thioctic acid phenol ester derivative as well as preparation method and application thereof

The invention provides a thioctic acid phenol ester derivative as well as a preparation method and application thereof. The thioctic acid phenol ester derivative has a general molecular formula with a formula (I), the formula (I) is shown in the description, wherein X is halogen and R is substituted phenyl. The thioctic acid phenol ester derivative provided by the invention has a novel structure and relatively high bioactivity and has a relatively good inhibition effect on proliferation and migration of tumor cells; compared with an inhibition effect of cis-platinum on the tumor cells, the inhibition effect of the carbamoyl substituted thioctic acid phenol ester derivative provided by the invention on tumors is better than inhibition strength of the cis-platinum on the tumor cells.

5-Bromo- and 3,5-dibromo-2-hydroxy-N-phenylbenzamides - Inhibitors of photosynthesis

5-Bromo-(Br-PBA) and 3,5-dibromo-2-hydroxy-N-phenylbenzamides (Br 2-PBA) inhibited photosynthetic electron transport (PET) and their inhibitory efficiency depended on the compound lipophilicity as well as on the electronic properties of the R substituent in the N-phenyl moiety. Br-PBA showed higher PET inhibiting activity than Br2-PBA with the same R substituent. The most effective inhibitors in the tested series were the derivatives with R = 3-F (Br-PBA; IC50 = 4.3 μmol dm-3) and R = 3-Cl (Br2-PBA; IC50 = 8.6 μmol dm -3). Bilinear dependence of the PET inhibiting activity on the lipophilicity of the compounds as well as on the Hammett constant, σ, of the R substituent was observed for both investigated series. Using EPR spectroscopy it was found that the site of action of the tested compounds in the photosynthetic apparatus is situated on the donor side of PS 2, in D · or in the Z·/D· intermediates. Interaction of the studied compounds with chlorophyll a and aromatic amino acids present in the pigment-protein complexes mainly in photosystem 2 was documented by fluorescence spectroscopy.